Surfactant protein A as a biomarker of outcomes of anti-fibrotic drug therapy in patients with idiopathic pulmonary fibrosis

Surfactant protein A as a biomarker of outcomes of anti-fibrotic drug therapy in patients with idiopathic pulmonary fibrosis

Abstract Background Idiopathic pulmonary fibrosis (IPF) is a progressive and fibrosing lung disease with poor prognosis. Pirfenidone and nintedanib are anti-fibrotic drugs used for patients with IPF. These drugs reduce the rate of decline in forced vital capacity (FVC). Serum surfactant protein (SP)...

Full description

Bibliographic Details
Main Authors: Takumi Yoshikawa, Mitsuo Otsuka, Hirofumi Chiba, Kimiyuki Ikeda, Yuki Mori, Yasuaki Umeda, Hirotaka Nishikiori, Koji Kuronuma, Hiroki Takahashi
Format: Article
Language:English
Published: BMC 2020-01-01
Series:BMC Pulmonary Medicine
Subjects:
Surfactant protein-A (SP-A)
Surfactant protein-D (SP-D)
Krebs von den Lungen-6 (KL-6)
Idiopathic pulmonary fibrosis (IPF)
Pirfenidone
Nintedanib
Online Access:https://doi.org/10.1186/s12890-020-1060-y

Internet

https://doi.org/10.1186/s12890-020-1060-y

Similar Items